CD4 and neoplasm: The ability of mTAK-500 to drive antitumor efficacy via an innate-to-adaptive immune cell engagement was further supported by the selective elimination of MDSCs, tumor-associated macrophages (TAM), DCs, and CD4+ or CD8+ T cells prior to treatment with mTAK-500.